Chief Accounting Officer
Arcutis Biotherapeutics, Inc. (ARQT)Equibles does not estimate personal net worth.
Get an email with a short summary when Arcutis Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARQT alertsScott Burrows is recorded as Chief Accounting Officer at Arcutis Biotherapeutics, Inc. (ARQT) since April 1, 2021. Arcutis Biotherapeutics, Inc. reported in an 8-K filed August 18, 2023 that Scott Burrows resigned as chief financial officer, effective August 31, 2023. The proxy statement of Arcutis Biotherapeutics, Inc. reports total compensation of $1,246,136 for Scott Burrows in fiscal 2022, including a base salary of $386,667. Disclosed compensation is on record for 2 fiscal years. Scott Burrows has spoken on 4 earnings calls across 1 company, most recently for Arcutis Biotherapeutics, Inc. on August 8, 2023. Arcutis Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arcutis Biotherapeutics, Inc. includes Todd Franklin Watanabe (CEO and Board Member), Latha Vairavan (CFO), Masaru Matsuda (General Counsel) and 7 others.
“On August 15, 2023, Scott Burrows notified Arcutis Biotherapeutics, Inc. (the "Company") of his decision to resign as chief financial officer of the Company, effective as of August 31, 2023.”
“Total revenues were $5.2 million in the second quarter. Net product revenues were $4.8 million driven by nearly 40% quarter-over-quarter demand growth as well as improved gross-to-net.”
“Net product revenues were $3 million in the first quarter, in line with our prior guidance. Strong unit demand growth, which doubled sequentially, was offset by the anticipated higher gross-to-net in Q1.”
“Net product revenues were $3 million for our first full quarter of launch driven by ZORYVE steady growth in unit demand. Our gross-to-net discount rate improved modestly in the quarter and continues to be meaningfully better than other recent branded topical launches at similar time points.”
“We had a couple of very important and exciting financial milestones in the third quarter. First, with the ZORYVE launch in August, the quarter represents our first as a revenue-generating company.”
2021-04-01–present
Start not stated–2023-08-31
Biotechnology · Healthcare
Chief Accounting Officer
2021-04-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $386,667 | $1,246,136 |
| 2021 | Arcutis Biotherapeutics, Inc. (ARQT) | Chief Financial Officer | $330,750 | $2,080,377 |
